Nasus Pharma is trading at $3.30, down -7.04%, as broader risk-off sentiment intensified on September 10, 2026.
- U.S. stocks weakened after August PPI rose 5.4% year over year, exceeding expectations and pressuring rate-cut hopes.
- No new company-specific announcement was identified; the decline appears aligned with broader market weakness and higher-rate concerns.